메뉴 건너뛰기
Oncologist
Volumn 18, Issue 4, 2013, Pages
Geographic tongue induced by angiogenesis inhibitors
Author keywords

Benign migratory glossitis; Bevacizumab; Geographic tongue; Sorafenib; Sunitinib
Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; SORAFENIB; SUNITINIB;
EID: 84877086859     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0320     Document Type: Letter
Times cited : (21)
References (6)
  • 1
    • 84857417613 scopus 로고    scopus 로고
    • Characteristics of oral mucosal events related to bevacizumab treatment
    • Gavrilovic IT, Balagula Y, Rosen AC et al. Characteristics of oral mucosal events related to bevacizumab treatment. The Oncologist 2012;17:274-278.
    • (2012) The Oncologist , vol.17 , pp. 274-278
    • Gavrilovic, I.T.1    Balagula, Y.2    Rosen, A.C.3
  • 2
    • 0037115519 scopus 로고    scopus 로고
    • Benign migratory glossitis or geographic tongue: An enigmatic oral lesion
    • Assimakopoulos D, Patrikakos G, Fotika C et al. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med 2002; 113:751-755.
    • (2002) Am J Med , vol.113 , pp. 751-755
    • Assimakopoulos, D.1    Patrikakos, G.2    Fotika, C.3
  • 3
    • 33144483703 scopus 로고    scopus 로고
    • Vascular endothelial growth factor localization in the adult
    • Maharaj ASR, Saint-Gebiez M, Maldonado AE et al. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006;168:639-648.
    • (2006) Am J Pathol , vol.168 , pp. 639-648
    • Maharaj, A.S.R.1    Saint-Gebiez, M.2    Maldonado, A.E.3
  • 4
    • 78649279329 scopus 로고    scopus 로고
    • inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO modelof oral carcinogenesis
    • Zhou G, Hasina R, Wroblewski K et al. inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO modelof oral carcinogenesis. Cancer Prev Res 2010; 3:1493-1502.
    • (2010) Cancer Prev Res , vol.3 , pp. 1493-1502
    • Zhou, G.1    Hasina, R.2    Wroblewski, K.3
  • 5
    • 84856267919 scopus 로고    scopus 로고
    • Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: A structured literature review
    • Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. The Oncologist 2012;17:135-144.
    • (2012) The Oncologist , vol.17 , pp. 135-144
    • Boers-Doets, C.B.1    Epstein, J.B.2    Raber-Durlacher, J.E.3
  • 6
    • 71949112710 scopus 로고    scopus 로고
    • Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib
    • Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-1051.
    • (2009) Br J Dermatol , vol.161 , pp. 1045-1051
    • Lee, W.J.1    Lee, J.L.2    Chang, S.E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.